Olga V Demler

List of Publications by Year in Descending Order

43 papers	33,625 citations	24 h-index	45 g-index
45 ext. papers	37,575 ext. citations	7.7 avg, IF	6.75 L-index

#	Paper	IF	Citations
43	Quantitative Comparison of Statistical Methods for Analyzing Human Metabolomics Data. *Metabolites*, **2022**, 12, 519	5.6	1
42	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. *JAMA Cardiology*, **2021**, 6, 437-447	16.2	27
41	Metabolomic Effects of Hormone Therapy and Associations With Coronary Heart Disease Among Postmenopausal Women. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002977	5.2	2
40	Using Administrative Data to Predict Suicide After Psychiatric Hospitalization in the Veterans Health Administration System. *Frontiers in Psychiatry*, **2020**, 11, 390	5	18
39	Quantum approximate Bayesian computation for NMR model inference. *Nature Machine Intelligence*, **2020**, 2, 396-402	22.5	4
38	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL. *Journal of Clinical Lipidology*, **2020**, 14, 241-251	4.9	7
37	Clinical Characteristics and Severity of COVID-19 Disease in Patients from Boston Area Hospitals **2020**,		5
36	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19 **2020**,		4
35	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). *Metabolites*, **2020**, 10,	5.6	4
34	Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. *Journal of the American Heart Association*, **2020**, 9, e016507	6	8
33	Pleiotropy-Based Decomposition of Genetic Risk Scores: Association and Interaction Analysis for Type 2 Diabetes and CAD. *American Journal of Human Genetics*, **2020**, 106, 646-658	11	6
32	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. *JAMA Network Open*, **2020**, 3, e2025466	10.4	6
31	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. *Statistics in Medicine*, **2019**, 38, 3817-3831	2.3	4
30	Statistical Workflow for Feature Selection in Human Metabolomics Data. *Metabolites*, **2019**, 9,	5.6	25
29	A Single Visualization Technique for Displaying Multiple Metabolite-Phenotype Associations. *Metabolites*, **2019**, 9,	5.6	9
28	Serum 25-hydroxyvitamin D in the VITamin D and OmegA-3 TriaL (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. *Contemporary Clinical Trials*, **2019**, 87, 105854	2.3	13
27	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002157	5.2	79

#	Reference	IF	Citations
26	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. *JAMA Network Open*, **2018**, 1, e185708	10.4	37
25	Reclassification calibration test for censored survival data: performance and comparison to goodness-of-fit criteria. *Diagnostic and Prognostic Research*, **2018**, 2,	5.5	4
24	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *Circulation*, **2017**, 135, 2494-2504	16.7	126
23	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. *Journal of Clinical Lipidology*, **2017**, 11, 1257-1267.e2	4.9	28
22	Clinical risk reclassification at 10 years. *Statistics in Medicine*, **2017**, 36, 4498-4502	2.3	6
21	Asymptotic distribution of ΔAUC, NRIs, and IDI based on theory of U-statistics. *Statistics in Medicine*, **2017**, 36, 3334-3360	2.3	12
20	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. *Clinical Chemistry*, **2015**, 61, 1156-63	5.5	38
19	Tests of calibration and goodness-of-fit in the survival setting. *Statistics in Medicine*, **2015**, 34, 1659-80	2.3	156
18	Impact of correlation on predictive ability of biomarkers. *Statistics in Medicine*, **2013**, 32, 4196-210	2.3	16
17	Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. *Statistics in Medicine*, **2012**, 31, 101-13	2.3	192
16	Misuse of DeLong test to compare AUCs for nested models. *Statistics in Medicine*, **2012**, 31, 2577-87	2.3	141
15	Pencina et al. respond to "The incremental value of new markers" and "Clinically relevant measures? A note of caution". *American Journal of Epidemiology*, **2012**, 176, 492-4	3.8	4
14	Equivalence of improvement in area under ROC curve and linear discriminant analysis coefficient under assumption of normality. *Statistics in Medicine*, **2011**, 30, 1410-8	2.3	25
13	The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. *American Journal of Psychiatry*, **2006**, 163, 716-23	11.9	2464
12	Changing profiles of service sectors used for mental health care in the United States. *American Journal of Psychiatry*, **2006**, 163, 1187-98	11.9	148
11	The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. *Psychological Medicine*, **2005**, 35, 245-56	6.9	1796
10	The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). *Biological Psychiatry*, **2005**, 58, 668-76	7.9	256
9	Prevalence and treatment of mental disorders, 1990 to 2003. *New England Journal of Medicine*, **2005**, 352, 2515-23	59.2	1249

8	Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*, **2005**, 62, 593-602		11859
7	Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*, **2005**, 62, 617-27		7753
6	The US National Comorbidity Survey Replication (NCS-R): design and field procedures. *International Journal of Methods in Psychiatric Research*, **2004**, 13, 69-92	4.3	644
5	Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). *International Journal of Methods in Psychiatric Research*, **2004**, 13, 122-39	4.3	370
4	Comorbid mental disorders account for the role impairment of commonly occurring chronic physical disorders: results from the National Comorbidity Survey. *Journal of Occupational and Environmental Medicine*, **2003**, 45, 1257-66	2	215
3	The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA - Journal of the American Medical Association*, **2003**, 289, 3095-105	27.4	5502
2	Adequacy of treatment for serious mental illness in the United States. *American Journal of Public Health*, **2002**, 92, 92-8	5.1	309
1	The effects of co-morbidity on the onset and persistence of generalized anxiety disorder in the ICPE surveys. International Consortium in Psychiatric Epidemiology. *Psychological Medicine*, **2002**, 32, 1213-25	6.9	53